AtriCure wraps up its $34M deal for an ablation specialist

AtriCure ($ATRC) has closed its deal for California's Estech, handing over $34 million to get its hands on some new surgical ablation technologies. AtriCure, a major player in the atrial fibrillation device market, expects Estech's instruments to help pad its earnings starting in 2015. More

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.